Immix Biopharma (IMMX) closed its previously announced underwritten offering of 11.4 million common shares at $11 each, raising net proceeds of about $117.1 million, the company said Wednesday.
The company plans to use the proceeds to fund development of NXC-201, working capital and general corporate purposes.